Role of Hippo/YAP signaling in irradiation-induced glioma cell apoptosis

References

• Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol. 2017;19:v1–v88. doi:10.1093/neuonc/nox15829117289
   PubMed Web of Science ®Google Scholar
• Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 2012;14(Suppl 5):v1–v49. doi:10.1093/neuonc/nos21823095881
   PubMed Web of Science ®Google Scholar
• Naidu MD, Mason JM, Pica RV, Fung H, Pena LA. Radiation resistance in glioma cells determined by DNA damage repair activity of Ape1/Ref-1. J Radiat Res. 2010;51:393–404. doi:10.1269/jrr.0907720679741
   PubMed Web of Science ®Google Scholar
• Tapon N, Harvey KF, Bell DW, et al. Salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell. 2002;110:467–478. doi:10.1016/s0092-8674(02)00824-312202036
   PubMed Web of Science ®Google Scholar
• He C, Mao D, Hua G, et al. Davis JS and Wang C. The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression. EMBO Mol Med. 2015;7:1426–1449. doi:10.15252/emmm.20140497626417066
   PubMed Web of Science ®Google Scholar
• Yimlamai D, Fowl BH, Camargo FD. Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer. J Hepatol. 2015;63:1491–1501. doi:10.1016/j.jhep.2015.07.00826226451
   PubMed Web of Science ®Google Scholar
• Song R, Gu D, Zhang L, et al. Functional significance of Hippo/YAP signaling for drug resistance in colorectal cancer. Mol Carcinog. 2018;57:1608–1615. doi:10.1002/mc.2288330074279
   PubMed Web of Science ®Google Scholar
• Liu AM, Xu MZ, Chen J, Poon RT, Luk JM. Targeting YAP and Hippo signaling pathway in liver cancer. Expert Opin Ther Targets. 2010;14:855–868. doi:10.1517/14728222.2010.49936120545481
   PubMed Web of Science ®Google Scholar
• Pan D. The hippo signaling pathway in development and cancer. Dev Cell. 2010;19:491–505. doi:10.1016/j.devcel.2010.09.01120951342
   PubMed Web of Science ®Google Scholar
• Fernandez LA, Squatrito M, Northcott P, et al. Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation. Oncogene. 2012;31:1923–1937. doi:10.1038/onc.2011.37921874045
   PubMed Web of Science ®Google Scholar
• Wang DY, Wu YN, Huang JQ, et al. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance. Chin J Cancer. 2016;35:47. doi:10.1186/s40880-016-0109-z27206784
   PubMedGoogle Scholar
• Xing Y, Liu Y, Liu T, et al. TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway. Cell Commun Signal. 2018;16:43. doi:10.1186/s12964-018-0254-x30064446
   PubMed Web of Science ®Google Scholar
• Han X, Xue X, Zhou H, Zhang G. A molecular view of the radioresistance of gliomas. Oncotarget. 2017;8:100931–100941. doi:10.18632/oncotarget.2175329246031
   PubMedGoogle Scholar
• Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol. 2008;9:288–296. doi:10.1016/S1470-2045(08)70073-118308254
   PubMed Web of Science ®Google Scholar
• Alhajala HS, Nguyen HS, Shabani S, et al. Irradiation of pediatric glioblastoma cells promotes radioresistance and enhances glioma malignancy via genome-wide transcriptome changes. Oncotarget. 2018;9:34122–34131. doi:10.18632/oncotarget.2613730344926
   PubMedGoogle Scholar
• Qu W, Li D, Wang Y, Wu Q, Hao D. Activation of sonic hedgehog signaling is associated with human osteosarcoma cells radioresistance characterized by increased proliferation, migration, and invasion. Med Sci Monit. 2018;24:3764–3771. doi:10.12659/MSM.90827829864766
   PubMed Web of Science ®Google Scholar
• Halder G, Johnson RL. Hippo signaling: growth control and beyond. Development. 2011;138:9–22. doi:10.1242/dev.04550021138973
   PubMed Web of Science ®Google Scholar
• Yu FX, Guan KL. The Hippo pathway: regulators and regulations. Genes Dev. 2013;27:355–371. doi:10.1101/gad.210773.11223431053
   PubMed Web of Science ®Google Scholar
• Xiang L, Gilkes DM, Hu H, et al. Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype. Oncotarget. 2014;5:12509–12527. doi:10.18632/oncotarget.299725587023
   PubMed Web of Science ®Google Scholar
• Mo J-S, Park HW, Guan K-L. The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 2014;15:642–656. doi:10.15252/embr.20143863824825474
   PubMed Web of Science ®Google Scholar
• Sebio A, Lenz HJ. Molecular pathways: hippo signaling, a critical tumor suppressor. Clin Cancer Res. 2015;21:5002–5007. doi:10.1158/1078-0432.CCR-15-041126384319
   PubMed Web of Science ®Google Scholar
• Zanconato F, Battilana G, Cordenonsi M, Piccolo S. YAP/TAZ as therapeutic targets in cancer. Curr Opin Pharmacol. 2016;29:26–33. doi:10.1016/j.coph.2016.05.00227262779
   PubMed Web of Science ®Google Scholar
• Liu AM, Poon RT, Luk JM. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun. 2010;394:623–627. doi:10.1016/j.bbrc.2010.03.03620226166
   PubMed Web of Science ®Google Scholar
• Jiang Z, Zhou C, Cheng L, et al. Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions. J Exp Clin Cancer Res. 2018;37:69. doi:10.1186/s13046-018-0740-429587800
   PubMed Web of Science ®Google Scholar
• Yuan M, Tomlinson V, Lara R, et al. Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ. 2008;15:1752–1759. doi:10.1038/cdd.2008.10818617895
   PubMed Web of Science ®Google Scholar
• Zhang H, Geng D, Gao J, et al. Expression and significance of Hippo/YAP signaling in glioma progression. Tumour Biol. 2016. doi:10.1007/s13277-016-5318-1
   Google Scholar
• Baia GS, Caballero OL, Orr BA, et al. Yes-associated protein 1 is activated and functions as an oncogene in meningiomas. Mol Cancer Res. 2012;10:904–913. doi:10.1158/1541-7786.MCR-12-011622618028
   PubMed Web of Science ®Google Scholar
• Orr BA, Bai H, Odia Y, Jain D, Anders RA, Eberhart CG. Yes-associated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth. J Neuropathol Exp Neurol. 2011;70:568–577. doi:10.1097/NEN.0b013e31821ff8d821666501
   PubMed Web of Science ®Google Scholar
• Zhang L, Cheng F, Wei Y, Guo D, Wang B, Li W. Inhibition of TAZ contributes radiation-induced senescence and growth arrest in glioma cells. Oncogene. 2019;38:2788–2799.30542117
   PubMed Web of Science ®Google Scholar
• Leng RP, Lin Y, Ma W, et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell. 2003;112:779–791. doi:10.1016/s0092-8674(03)00193-412654245
   PubMed Web of Science ®Google Scholar
• Jung YS, Qian Y, Chen X. The p73 tumor suppressor is targeted by Pirh2 RING finger E3 ubiquitin ligase for the proteasome-dependent degradation. J Biol Chem. 2011;286:35388–35395. doi:10.1074/jbc.M111.26153721852228
   PubMed Web of Science ®Google Scholar
• Jung YS, Qian Y, Yan W, Chen X. Pirh2 E3 ubiquitin ligase modulates keratinocyte differentiation through p63. J Invest Dermatol. 2013;133:1178–1187. doi:10.1038/jid.2012.46623235527
   PubMed Web of Science ®Google Scholar